Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer

Blazeby, Jane; Alderson, Derek; Winstone, K; Steyn, Richard; Hammerlid, Eva; Arrarás, Juan Ignacio; Farndon, John

doi:10.1016/0959-8049(96)00199-2

Cited by 167 publications

(114 citation statements)

References 15 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…Items with mean score o1.5 in the entire series and in two of the three subgroups were considered for exclusion. 19 Items fulfilling these exclusion criteria, but having a range of three in the entire series and in at least one of the subgroups were retained. Results from the debriefing interview were also taken into account when deciding on exclusion of items.…”

Section: Discussionmentioning

confidence: 99%

The EORTC Ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30). Development and Pre-Testing (Phase I-III)

Brandberg

Damato

Kivelä

et al. 2004

Eye

View full text Add to dashboard Cite

Aims The research objective was to develop a questionnaire module to be used, in addition to the European Organisation into Research and Treatment of Cancer (EORTC) QLQ-C30, for measurement of quality of life (QL) among patients with uveal melanoma treated with methods such as transpupillary thermotherapy, plaque radiotherapy, proton beam radiotherapy, local resection, and enucleation. The present paper describes the development through Phases I-III. Methods Relevant QL issues were generated from literature search and from interviews with ophthalmologists, nurses, and patients with uveal melanoma representing three major treatment options: enucleation, plaque brachytherapy, and proton beam therapy. Results The provisional module was pretested in 61 patients from Finland, Sweden, and UK. The EORTC QLQ-OPT30 module consists of 26 items for all patients, and four additional items for patients receiving treatments other than enucleation. It measures ocular irritation, vision impairment, headache, worry about recurrent disease, problems with driving, problems with appearance functional problems due to vision impairment, and problems reading. Conclusions Several treatment modalities are available for uveal melanoma. There is limited knowledge of the impact of these treatments on QL in the long and short term. We hope that the OPT30 module together with the EORTC QLQ-C30 core questionnaire can be a useful tool in research.

show abstract

Section: Discussionmentioning

confidence: 99%

The EORTC Ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30). Development and Pre-Testing (Phase I-III)

Brandberg

Damato

Kivelä

et al. 2004

Eye

View full text Add to dashboard Cite

show abstract

“…In addition, few measures include an assessment of dysphagia, which is an important symptom to assess in patients with cancer of the upper gastrointestinal tract. The EORTC oesophageal and gastric modules include this and other relevant symptoms that most clinicians consider important in evaluation of treatment (Blazeby et al, 1996;Vickery et al, 2001;Blazeby et al, 2003).…”

Section: Discussionmentioning

confidence: 99%

“…The QLQ-C30 has been reported in detail elsewhere and has been validated in patients with many diagnoses including cancer of the upper gastrointestinal tract. The oesophageal (QLQ-OES18) and gastric (QLQ-STO22) modules have undergone strict questionnaire development and are widely used (Blazeby et al, 1996;Vickery et al, 2001). The QLQ-OES18 has recently completed international validation testing (Blazeby et al, 2003) and the QLQ-STO22 is currently being validated in EORTC protocol 15012.…”

Section: Quality Of Life Questionnairesmentioning

confidence: 99%

Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer

et al. 2003

View full text Add to dashboard Cite

Quality of life (QOL) is an important outcome after treatment for upper gastrointestinal tract cancer but few studies report good accrual and subsequent attrition is usually high. This study investigated the feasibility of a nurse-led service to obtain longitudinal QOL assessments and explored how clinical and sociodemographic factors influence patients' need for help to complete questionnaires. Fully informed patients were invited into the study. Baseline hospital assessments were scheduled by telephone and thereafter by post unless patients' health indicated the need for a home visit. In all, 128 out of 140 (91%) baseline QOL assessments were performed. Follow-up questionnaire completion was good, with 114 patients (89%) completing all but one of the expected assessments. At baseline, 41 (32%) patients required a lot of help to complete questionnaires. Patients requiring help were more likely to be undergoing palliative treatment than treatment aimed at cure (68 vs 33%; odds ratio 3.48, Po0.01). Patients' with advanced stage cancer of the upper gastrointestinal tract receiving palliative treatment require dedicated staff to ensure good compliance with longitudinal QOL data collection. It is essential to budget for this in clinical trails.

show abstract

“…The instrument covers specific esophageal cancer symptoms during the last week, such as dysphagia, eating, reflux, pain, difficulty swallowing saliva, choking on swallowing, dry mouth, taste problems, problems with coughing and speaking difficulty [22].…”

Section: Quality Of Life Questionnairesmentioning

confidence: 99%

Quality of Life during Neoadjuvant Therapy for Patients with Esophageal Cancer

Guedes¹,

Nascimento²,

Porto³

et al. 2017

IOSR JNHS

View full text Add to dashboard Cite

Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer

Cited by 167 publications

References 15 publications

The EORTC Ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30). Development and Pre-Testing (Phase I-III)

The EORTC Ophthalmic Oncology Quality of Life Questionnaire Module (EORTC QLQ-OPT30). Development and Pre-Testing (Phase I-III)

Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer

Quality of Life during Neoadjuvant Therapy for Patients with Esophageal Cancer

Contact Info

Product

Resources

About